Pfizer and US drug regulators are revising information for use and monitoring of the company’s Covid-19 vaccine developed with BioNTech, after rare allergic reactions were seen in some recipients.

The revisions reflect guidelines from the Centers for Disease Control and Prevention (CDC) for following vaccine recipients and managing potential reactions, Doran Fink, deputy director of Food and Drug Administration’s (FDA’s) division of vaccines and related products applications, said on Thursday in a meeting of FDA advisers...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.